Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Arcturus Therapeutics Holdings (ARCT) over the last 4 years, with Dec 2024 value amounting to -$3.

  • Arcturus Therapeutics Holdings' EPS (Weighted Average and Diluted) fell 88.46% to -$0.49 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.46, marking a year-over-year decrease of 5.13%. This contributed to the annual value of -$3 for FY2024, which is 167.86% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported EPS (Weighted Average and Diluted) of -$3 as of FY2024, which was down 167.86% from -$1.12 recorded in FY2023.
  • Arcturus Therapeutics Holdings' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.35 during FY2022, with a 5-year trough of -$7.74 in FY2021.
  • In the last 3 years, Arcturus Therapeutics Holdings' EPS (Weighted Average and Diluted) had a median value of -$1.12 in 2023 and averaged -$1.26.
  • In the last 5 years, Arcturus Therapeutics Holdings' EPS (Weighted Average and Diluted) skyrocketed by 104.52% in 2022 and then plummeted by 420.00% in 2023.
  • Yearly analysis of 4 years shows Arcturus Therapeutics Holdings' EPS (Weighted Average and Diluted) stood at -$7.74 in 2021, then surged by 104.52% to $0.35 in 2022, then plummeted by 420.00% to -$1.12 in 2023, then crashed by 167.86% to -$3 in 2024.